David Palchak, MD
Hematology & Oncology · Arroyo Grande, CANPI 1396815965
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (39.5%), food and beverage and gifts — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Novartis at 57.7% of the total. Reporting peaked in 2021 at $1,150 and has fallen 62.9% since, to $426 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 124 payments — averaging $33.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Seagen Inc.$252
- Eisai Inc.$198
- Boehringer Ingelheim$179
- Takeda Pharmaceuticals U.S.A., Inc.$156
- Merck$98
- plus $845 from 25 others
Across 48 payments — averaging $9376.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aadi Bioscience, Inc.$321K
- Novartis$123K
- Incyte Corporation$5K
- Merck$528
What the payments were for
- Food & beverage$1,48036%
- Education$2566%
- Gifts$74218%
- Other$1,61539%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 38 | $2,363 |
| Seagen Inc. | 13 | $252 |
| Eisai Inc. | 11 | $198 |
| Boehringer Ingelheim | 11 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $156 |
| Merck | 6 | $98 |
| Johnson & Johnson | 3 | $98 |
| AbbVie | 4 | $94 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $66 |
| Secura Bio, Inc. | 4 | $64 |
| AstraZeneca | 3 | $61 |
| Pfizer | 3 | $56 |
| Rigel Pharmaceuticals, Inc. | 1 | $40 |
| Agios Pharmaceuticals, Inc. | 2 | $37 |
| Caris MPI, Inc. | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $27 |
| ADC Therapeutics America, Inc. | 1 | $24 |
| EMD Serono, Inc. | 1 | $23 |
| Gilead | 2 | $23 |
| Foundation Medicine, Inc. | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Acrotech Biopharma Inc. | 1 | $18 |
| Sobi, Inc | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Exelixis Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Mirati Therapeutics, Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $14 |
| GSK | 1 | $14 |
| Heron Therapeutics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISQALI$270
How this compares
$4,092 in reported general payments places this provider in the 50th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 36 | $653,071 |
| PomalystPomalidomide | 17 | $495,480 |
| Lenalidomide | 27 | $323,246 |
| RevlimidLenalidomide | 17 | $321,200 |
| ImbruvicaIbrutinib | 17 | $290,732 |
| VerzenioAbemaciclib | 15 | $221,149 |
| VenclextaVenetoclax | 17 | $144,108 |
| AlecensaAlectinib Hcl | 11 | $95,733 |
| ZarxioFilgrastim-Sndz | 14 | $34,321 |
| OrgovyxRelugolix | 11 | $29,828 |
| EliquisApixaban | 33 | $18,917 |
| XareltoRivaroxaban | 13 | $17,014 |
| Abiraterone Acetate | 11 | $8,712 |
| CreonLipase/Protease/Amylase | 11 | $6,962 |
| Tamoxifen Citrate | 66 | $1,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $61 | $653,07136 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $22 | $495,48017 claims |
| Bristol Myers SquibbRevlimid | $14 | $321,20017 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $66 | $290,73217 claims |
| AbbVieVenclexta, Creon | $94 | $151,07028 claims |
| Genentech USA, Inc.Alecensa | $18 | $95,73311 claims |
| PfizerEliquis | $56 | $18,91733 claims |
| Johnson & JohnsonXarelto | $98 | $17,01413 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $22 | $34525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Arroyo Grande
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.